These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

957 related articles for article (PubMed ID: 17597252)

  • 1. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.
    Blagden N; de Matas M; Gavan PT; York P
    Adv Drug Deliv Rev; 2007 Jul; 59(7):617-30. PubMed ID: 17597252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.
    Morissette SL; Almarsson O; Peterson ML; Remenar JF; Read MJ; Lemmo AV; Ellis S; Cima MJ; Gardner CR
    Adv Drug Deliv Rev; 2004 Feb; 56(3):275-300. PubMed ID: 14962582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of cocrystals in pharmaceutical science.
    Shan N; Zaworotko MJ
    Drug Discov Today; 2008 May; 13(9-10):440-6. PubMed ID: 18468562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Supercritical fluid particle design for poorly water-soluble drugs (review).
    Sun Y
    Curr Pharm Des; 2014; 20(3):349-68. PubMed ID: 23651403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prodrug approaches for enhancing the bioavailability of drugs with low solubility.
    Müller CE
    Chem Biodivers; 2009 Nov; 6(11):2071-83. PubMed ID: 19937841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supercritical carbon dioxide processing of active pharmaceutical ingredients for polymorphic control and for complex formation.
    Moribe K; Tozuka Y; Yamamoto K
    Adv Drug Deliv Rev; 2008 Feb; 60(3):328-38. PubMed ID: 18006109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
    Dahan A; Hoffman A
    J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs.
    Vasconcelos T; Sarmento B; Costa P
    Drug Discov Today; 2007 Dec; 12(23-24):1068-75. PubMed ID: 18061887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel ultra-rapid freezing particle engineering process for enhancement of dissolution rates of poorly water-soluble drugs.
    Overhoff KA; Engstrom JD; Chen B; Scherzer BD; Milner TE; Johnston KP; Williams RO
    Eur J Pharm Biopharm; 2007 Jan; 65(1):57-67. PubMed ID: 16987642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of dissolution rate of poorly-soluble active ingredients by supercritical fluid processes. Part I: Micronization of neat particles.
    Perrut M; Jung J; Leboeuf F
    Int J Pharm; 2005 Jan; 288(1):3-10. PubMed ID: 15607252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs.
    Kawakami K
    Adv Drug Deliv Rev; 2012 May; 64(6):480-95. PubMed ID: 22265844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
    Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S
    Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceutical cocrystals and poorly soluble drugs.
    Thakuria R; Delori A; Jones W; Lipert MP; Roy L; Rodríguez-Hornedo N
    Int J Pharm; 2013 Aug; 453(1):101-25. PubMed ID: 23207015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solid-state interactions of calixarenes with biorelevant molecules.
    Danylyuk O; Suwinska K
    Chem Commun (Camb); 2009 Oct; (39):5799-813. PubMed ID: 19787105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fast-dissolving microparticles fail to show improved oral bioavailability.
    Wong SM; Kellaway IW; Murdan S
    J Pharm Pharmacol; 2006 Oct; 58(10):1319-26. PubMed ID: 17034654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Progress in the research of amorphous pharmaceuticals].
    Ying J; Lü Y; Du GH
    Yao Xue Xue Bao; 2009 May; 44(5):443-8. PubMed ID: 19618716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solid dispersions, part I: recent evolutions and future opportunities in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs.
    Bikiaris DN
    Expert Opin Drug Deliv; 2011 Nov; 8(11):1501-19. PubMed ID: 21919807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory aspects of drug dissolution from a European perspective.
    Graffner C
    Eur J Pharm Sci; 2006 Nov; 29(3-4):288-93. PubMed ID: 16950606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorph selection: the role of nucleation, crystal growth and molecular modeling.
    Erdemir D; Lee AY; Myerson AS
    Curr Opin Drug Discov Devel; 2007 Nov; 10(6):746-55. PubMed ID: 17987526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies to improve oral drug bioavailability.
    Gomez-Orellana I
    Expert Opin Drug Deliv; 2005 May; 2(3):419-33. PubMed ID: 16296764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.